ARCHIVES

Phase III Tecemotide Trial Fails OS Endpoint; Second Trial Planned After Subgroup Analysis

This article is from The Cancer Letter archive.

Vol. 36 No. 12 | December 27, 2013

Download PDF Visit The Full Archive

Related Articles

Lenalidomide Maintenance Increased PFS and Survival

May 25, 2012

Letters From Ovarian Cancer Survivors Shed Light On Their Psychological Distress

October 31, 2003

NCCS Networker Volume 2 Issue 2, Spring 1988

April 13, 1988

In Brief: Cancer Act, Accelerated Progress, ACS President Says; Scanners Scapegoats, EMI Chief Claimes

April 7, 1978

In Brief: House Money Bill Reportedly Will Not Increase

September 18, 1981

Drug Development: Herceptin Associated with 15 Deaths, Genentech Says

May 12, 2000